GT Biopharma Q3 2026 Results: Net Loss of $3.53M
GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.
- Key figure
- Net loss $3.53M